LENZ THERAPEUTICS, INC. SUPPORT AGREEMENTSupport Agreement • November 15th, 2023 • Graphite Bio, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS SUPPORT AGREEMENT (this “Agreement”), dated as of November [•], 2023 is made by and among Graphite Bio, Inc., a Delaware corporation (“Parent”), Lenz Therapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned holders (each a “Stockholder”) of shares of capital stock (the “Shares”) of the Company.
SUBSCRIPTION AGREEMENTSubscription Agreement • November 15th, 2023 • Graphite Bio, Inc. • Biological products, (no disgnostic substances) • Delaware
This SUBSCRIPTION AGREEMENT (this “Agreement”) is dated as of November 14, 2023 (the “Effective Date”), by and among Graphite Bio, Inc., a Delaware corporation (the “Company”), and the individuals and entities listed on Exhibit A attached to this Agreement (each, a “Purchaser” and together, the “Purchasers”).
AGREEMENT AND PLAN OF MERGER by and among GRAPHITE BIO, INC., GENERATE MERGER SUB, INC. and LENZ THERAPEUTICS, INC. Dated as of November 14, 2023Merger Agreement • November 15th, 2023 • Graphite Bio, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of November 14, 2023, by and among Graphite Bio, Inc., a Delaware corporation (“Parent”), Generate Merger Sub, Inc., a Delaware corporation (“Merger Sub”), and Lenz Therapeutics, Inc., a Delaware corporation (the “Company”).
LOCK-UP AGREEMENTLock-Up Agreement • November 15th, 2023 • Graphite Bio, Inc. • Biological products, (no disgnostic substances)
LENZ Therapeutics and Graphite Bio Announce Merger Agreement - Merger to create NASDAQ-listed, late clinical-stage biopharmaceutical company focused on advancing LENZ Therapeutics’ lead assets for the treatment of presbyopia - Combined company...Merger Agreement • November 15th, 2023 • Graphite Bio, Inc. • Biological products, (no disgnostic substances)
SAN DIEGO & SOUTH SAN FRANCISCO, Calif., - November 15, 2023 - (BUSINESS WIRE) — LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. (NASDAQ: GRPH) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The lead programs of the combined company will address presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over the age of 45. The combined company is expected to trade on Nasdaq under the ticker symbol “LENZ.”
